The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 10, 2015

Filed:

Dec. 17, 2010
Applicants:

Yasuyoshi Arikawa, Osaka, JP;

Benjamin Jones, Cardiff-By-The-Sea, CA (US);

Betty Lam, San Diego, CA (US);

Zhe Nie, San Diego, CA (US);

Christopher Smith, San Diego, CA (US);

Masashi Takahashi, Osaka, JP;

Qing Dong, San Diego, CA (US);

Victoria Feher, San Diego, CA (US);

Inventors:

Yasuyoshi Arikawa, Osaka, JP;

Benjamin Jones, Cardiff-By-The-Sea, CA (US);

Betty Lam, San Diego, CA (US);

Zhe Nie, San Diego, CA (US);

Christopher Smith, San Diego, CA (US);

Masashi Takahashi, Osaka, JP;

Qing Dong, San Diego, CA (US);

Victoria Feher, San Diego, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 487/04 (2006.01); A61K 31/519 (2006.01); A61P 35/00 (2006.01); A61P 29/00 (2006.01); A61P 11/06 (2006.01); A61P 17/06 (2006.01); A61P 25/28 (2006.01); C07D 471/04 (2006.01); A61K 31/437 (2006.01); A61K 31/527 (2006.01); A61K 45/06 (2006.01); C07D 487/10 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 31/437 (2013.01); A61K 31/519 (2013.01); A61K 31/527 (2013.01); A61K 45/06 (2013.01); C07D 471/04 (2013.01); C07D 487/10 (2013.01); C07D 519/00 (2013.01);
Abstract

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L, L, R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.


Find Patent Forward Citations

Loading…